Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing using the VENTANA® MET (SP44) RxDx assay, now available as an add-on to comprehensive genomic profiling (CGP) test orders for patients with non-squamous non-small cell lung cancer (NSCLC).
Using antibodies to detect specific proteins in tissue samples, Foundation Medicine’s IHC test offerings complement its CGP tests and together support healthcare providers to make well-informed treatment decisions for their patients. Foundation Medicine’s new MET (c-Met) IHC offering helps healthcare providers identify patients eligible for a first-in-class MET-directed antibody drug conjugate (ADC) for NSCLC patients with c-Met protein overexpression. With c-Met overexpression present in approximately 25% of NSCLC cases,1 this newly approved treatment offers a promising option for eligible patients.
Foundation Medicine’s IHC test offerings include:
- MET IHC testing, which helps identify patients with locally advanced or metastatic non-squamous NSCLC who exhibit high c-Met protein overexpression and may be eligible for a new targeted treatment.2
- CLDN18 (Claudin 18) IHC testing, which helps identify patients with gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2-positive, potentially qualifying them for a targeted treatment.3
- HER2 IHC testing, which helps identify patients with advanced HER2-positive solid tumors who may be eligible for a targeted treatment.4
- FOLR1 IHC testing, which helps identify patients with ovarian, fallopian tube, or primary peritoneal cancer whose tumors are folate receptor alpha-positive and who may be eligible for a targeted treatment.5
- Four PD-L1 IHC (22C3, 28-8, SP142, SP263) tests, which help identify patients who may benefit from immunotherapies; PD-L1 IHC testing has become a crucial tool for personalizing treatment strategies across various cancers, including NSCLC, triple negative breast cancer, cervical cancer, HER2-positive gastric/gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma.6
“IHC testing complements our high-quality biomarker tests, offering healthcare providers a streamlined, one-stop solution that empowers them to more accurately predict potential treatment selection and ensure patients receive the medicines most likely to work for them,” says Foundation Medicine’s Chief Commercial Officer Annie Murphy. “We are excited to expand our IHC offerings, including the newly introduced MET IHC test, which supports treatment decisions for certain patients with non-squamous NSCLC, a group that has historically faced limited treatment options and poor prognosis.”
Foundation Medicine plans to continue expansion of its IHC test offerings and is committed to launching new IHC tests rapidly following FDA approval of companion diagnostic kits to minimize delays in patient treatment.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
